California State Teachers Retirement System Raises Position in TG Therapeutics, Inc. $TGTX

California State Teachers Retirement System boosted its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 23.6% in the 1st quarter, HoldingsChannel.com reports. The firm owned 175,750 shares of the biopharmaceutical company’s stock after purchasing an additional 33,572 shares during the period. California State Teachers Retirement System’s holdings in TG Therapeutics were worth $5,838,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in TGTX. M&T Bank Corp purchased a new stake in shares of TG Therapeutics during the fourth quarter valued at approximately $3,750,000. Hsbc Holdings PLC grew its holdings in shares of TG Therapeutics by 228.7% in the fourth quarter. Hsbc Holdings PLC now owns 146,087 shares of the biopharmaceutical company’s stock worth $4,374,000 after purchasing an additional 101,646 shares during the last quarter. Gibbs Wealth Management purchased a new position in shares of TG Therapeutics in the fourth quarter worth $455,000. Vanguard Group Inc. increased its stake in shares of TG Therapeutics by 2.1% in the fourth quarter. Vanguard Group Inc. now owns 15,841,002 shares of the biopharmaceutical company’s stock worth $472,220,000 after buying an additional 319,703 shares during the period. Finally, Penn Capital Management Company LLC raised its holdings in TG Therapeutics by 3.2% during the 4th quarter. Penn Capital Management Company LLC now owns 538,117 shares of the biopharmaceutical company’s stock valued at $16,082,000 after buying an additional 16,857 shares during the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TGTX has been the subject of several analyst reports. Zacks Research raised shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, June 1st. Weiss Ratings restated a “hold (c+)” rating on shares of TG Therapeutics in a research report on Wednesday, July 29th. B. Riley Financial increased their target price on shares of TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a report on Monday, July 27th. HC Wainwright reissued a “buy” rating and issued a $78.00 target price on shares of TG Therapeutics in a research note on Tuesday. Finally, Bank of America boosted their price target on TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a report on Tuesday, July 7th. Five research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $58.67.

TG Therapeutics Price Performance

Shares of NASDAQ TGTX opened at $49.88 on Thursday. The company has a 50 day simple moving average of $51.02 and a two-hundred day simple moving average of $39.34. TG Therapeutics, Inc. has a fifty-two week low of $25.28 and a fifty-two week high of $59.30. The company has a market capitalization of $7.64 billion, a price-to-earnings ratio of 18.20, a P/E/G ratio of 1.25 and a beta of 1.62. The company has a debt-to-equity ratio of 1.28, a quick ratio of 5.12 and a current ratio of 5.81.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.26). TG Therapeutics had a return on equity of 73.23% and a net margin of 55.22%.The company had revenue of $240.34 million during the quarter, compared to analysts’ expectations of $229.77 million. During the same quarter in the previous year, the company earned $0.17 EPS. The business’s quarterly revenue was up 70.2% on a year-over-year basis. Analysts expect that TG Therapeutics, Inc. will post 1.42 EPS for the current fiscal year.

More TG Therapeutics News

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Strong revenue growth and raised outlook support the shares. TG Therapeutics reported second-quarter revenue of $240.34 million, ahead of the $229.77 million analyst estimate and up 70.2% year over year. The company also raised its 2026 outlook, helping counter concerns about the earnings miss. TG Therapeutics Is Down 15.9% After Q2 Miss But Raised 2026 Outlook
• Positive Sentiment: HC Wainwright maintained a Buy rating and $78 price target. The target implies substantial upside from recent trading levels and indicates the analyst continues to see value in TG Therapeutics’ growth prospects despite revisions to its earnings model.
• Neutral Sentiment: Near-term earnings expectations were mixed. HC Wainwright increased its fourth-quarter 2026 EPS forecast to $0.37 from $0.31, while maintaining estimates of $1.42 EPS for the current full year.
• Negative Sentiment: The quarterly EPS miss triggered investor concern. TG Therapeutics reported $0.05 in EPS versus the $0.31 consensus estimate, even though revenue exceeded expectations. The shortfall contributed to a steep initial decline in the stock. TG Therapeutics Stock Price Down 9% Following Weak Earnings
• Negative Sentiment: HC Wainwright reduced several future EPS estimates. Forecasts were lowered for 2026 to $0.86 from $0.99, 2027 to $2.16 from $2.32, 2028 to $3.58 from $3.81, 2029 to $4.53 from $4.70, and 2030 to $5.64 from $5.84. These cuts suggest expectations for the company’s profit ramp have moderated.

TG Therapeutics Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.